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Abstract
Background:  The use of artemisinin derivative-based combination therapy (ACT) such as
artesunate plus amodiaquine is currently recommended for the treatment of uncomplicated
Plasmodium falciparum malaria. Fixed-dose combinations are more adapted to patients than
regimens involving multiple tablets and improve treatment compliance. A fixed-dose combination
of artesunate + amodiaquine (ASAQ) was recently developed. To assess the efficacy and safety of
this new combination and to define its optimum dosage regimen (once or twice daily) in the
treatment of uncomplicated P. falciparum malaria, a multicentre clinical study was conducted.
Methods: A multicentre, randomized, controlled, investigator-blinded, parallel-group study was
conducted in five African centers in Cameroon, Madagascar, Mali and Senegal from March to
December 2006. Efficacy and safety of ASAQ were assessed compared to those of artemether +
lumefantrine (AL). The WHO protocol with a 28-day follow-up for assessing the drug therapeutic
efficacy was used. Patients suffering from uncomplicated P. falciparum malaria were randomized to
receive ASAQ orally once daily (ASAQ1), ASAQ twice daily (ASAQ2) or AL twice daily (AL) for
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three days. The primary outcome was PCR-corrected parasitological cure rate and clinical
response.
Results: Of 941 patients initially randomized and stratified into two age groups (<5 years, and ≥5
years), 936 (99.5%) were retained for the intent to treat (ITT) analysis, and 859 (91.3%) patients
for the per protocol (PP) analysis. Among ITT population, up to D28, PCR-corrected adequate
parasitological and clinical response rates were 95.2% in the ASAQ1 group, 94.9% in the ASAQ2
group and 95.5% in the AL group. Moreover, the cure rate evaluated among PP population was
≥98.5% in both ASAQ therapeutic arms. Therapeutic response rates did not display any significant
differences between age groups or between one geographical site and another. Altogether, this
demonstrates the non-inferiority of ASAQ1 regimen compared to both ASAQ2 and AL regimens.
During follow-up mild and moderate adverse events including gastrointestinal and/or nervous
disorders were reported in 29.3% of patients, with no difference between groups in the nature,
frequency or intensity of adverse events.
Conclusion: The non-inferiority of ASAQ compared with AL was demonstrated. The fixed-dose
combination artesunate + amodiaquine (ASAQ) is safe and efficacious even in young children under
5 years of age. Whilst administration on a twice-a-day basis does not improve the efficacy of ASAQ
significantly, a once-a-day intake of this new combination clearly appears as an effective and safe
therapy in the treatment of uncomplicated P. falciparum malaria both in adults and children.
Implications of such findings are of primary importance in terms of public health especially in African
countries. As most national policies plan to strengthen malaria control to reach the elimination of
this disease, anti-malarial drugs such as the artesunate + amodiaquine fixed-dose ACT will play a
pivotal role in this process.
Trial registration: The protocol was registered with the www.clinicaltrials.gov open clinical trial
registry under the identifier number NCT00316329.
Background
Combination therapy has been on the path to become the
treatment of choice for uncomplicated Plasmodium falci-
parum  malaria or the past decade [1]. The use of oral
artemisinin-based combination therapy (ACT) combin-
ing an artemisinin derivative with anti-malarial agents
with a long half-life is particularly encouraged. Rand-
omized clinical trials have previously demonstrated that
the combination of artesunate (AS) with amodiaquine
(AQ) could improve cure rates and reduce gametocytemia
more efficiently than a monotherapy with AQ alone [2].
Since this (AS) + (AQ) combination proved well-tolerated
too, a co-blister containing AS and AQ (such as Arsucam®)
was designed and marketed in 2002. The results of differ-
ent clinical trials confirmed the efficacy of Arsucam® in
Senegal [3,4], the Comoros Islands [5], Mali [6] and Cam-
eroon [4]. The efficacy of the AS + AQ combination was
confirmed by routine use as part of national malaria treat-
ment policy [7].
The 2006 WHO guidelines for malaria treatment recom-
mend the combination of AS and AQ in a ratio of 2.5 (cor-
responding to the theoretical dosage of both drugs used in
monotherapy) or 3.1 (corresponding to the co-blister's
ratio). However, the use of AS and AQ in multiple tablet
combinations is unsatisfactory in terms of treatment com-
pliance. It involves the risk that only one of the two drugs
be received or that the drugs be administered at an inade-
quate dose. Since it is recognized in the medical fields that
the availability of single-tablet formulations (containing
drugs in a fixed-dose combination) reduces these risks
and improves treatment compliance [8-10], such a combi-
nation was developed by a public-private partnership
between DNDi and sanofi-aventis, to provide AS and AQ
in a single tablet (ASAQ). A 1:2.7 dose-ratio of AS:AQ was
determined according to the accepted therapeutic doses of
the components individually. Finally, the dose regimen
was stratified by weight and age to ensure optimal doses
delivery [11]. In a first pivotal Phase III study performed
in Burkina Faso ASAQ showed non-inferiority to the com-
bination of AS and AQ in children with P. falciparum
infections [12]. In order to complete the phase III pro-
gram before WHO prequalification, a second multicentre
study was initiated, whose results are reported herein. The
objective of this study was to assess the efficacy and safety
of ASAQ fixed-dose combination tablets in comparison
with a fixed-dose combination of artemether + lumefan-
trine (AL), then to define the optimum dosage regimen of
ASAQ (1 or 2 daily intakes per day) in the treatment of
uncomplicated P. falciparum malaria.Malaria Journal 2009, 8:125 http://www.malariajournal.com/content/8/1/125
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Methods
Study design
This was a multicentre, randomized, controlled, investiga-
tor-blinded, parallel-group study comparing three ACT
regimens in patients with uncomplicated P. falciparum
malaria. The study was conducted in five African sites
where malaria transmission is perennial: Bancoumana
(Mali), Yaoundé (Cameroon), Tsiroanomandidy (Mada-
gascar), Keur-Socé and Mlomp (Senegal). Patients were
included between March and December 2006. The study
was conducted during the highest malaria transmission
period for each site. This protocol was registered with the
www.clinicaltrials.gov open clinical trial registry under
the identifier number NCT00316329.
Patients
The study included patients infected with P. falciparum
residing in the study area throughout the planned period
and according to the following criteria: weighing ≥ 10 kg;
displaying a parasitaemia from 1,000 to 200,000 asexual
forms per microliter of blood; presenting an axillary tem-
perature ≥ 37.5°C or suffering from fever within the last
24 hours and capable of receiving oral treatment.
Patients with any clinical sign of severe malaria [13] or
any serious concomitant disease, such as cardiovascular
disease were excluded. Similarly exclusion was applied in
case of concomitant intake of medications involving cyto-
chrome P450 2D6 (CYP2D6) pathway and in case of doc-
umented intolerance to any medications used in this
study. Pregnant or breast-feeding women were also
excluded and a urine pregnancy test was performed on all
women of child-bearing age. Successive enrolments in this
study or simultaneously in any other clinical trial were
also prohibited.
Randomization and treatment
Patients were randomized to one of three treatment
groups, namely ASAQ bi-layer fixed-dose combination
tablets once daily intake (ASAQ1), ASAQ twice daily
(ASAQ2), and AL twice daily (AL). Randomization was
stratified according to patient age using separate randomi-
zation lists. The two age strata were children under five
years of age (as the primary WHO target population) and
patients aged five years and over. Treatment dosages were
determined according to patient's body weight. Treatment
duration was three days. An eight hour time-lapse was
requested in case of twice-daily regimens (usually the
morning and evening doses). Tablets were orally adminis-
tered with a small amount of drinking water; and patients
were advised to resume a normal diet as soon as possible.
All patients were monitored for 30 minutes after adminis-
tration in order to ensure that the drug was not lost after
an eventual vomiting episode. When this occurred, the
same dose was re-administered. If vomiting re-occured,
the subject was withdrawn from the study and a replace-
ment treatment with another effective anti-malarial, gen-
erally quinine, was provided. In order to ensure blinding,
all patients in the same body weight range received the
same number of tablets per intake, which was defined by
the recommended dose of AL. Patients in the ASAQ arms
were given placebo tablets to match this number. Only the
person administering the treatment was aware of the
nature of the drug taken by each participant, whereas
investigators evaluating safety and efficacy were kept
blind.
Efficacy and safety assessment
The WHO protocol with a 28-day follow-up [14] to assess
the anti-malarial drug therapeutic efficacy was used (Table
1). Follow-up visits were systematically performed on
Days 1, 2, 3, 7, 14, 21 and 28 after enrolment. Each visit
Table 1: Investigational plan
STUDY PARAMETERS REFERENCE DAYS Unplanned visits
D0 D1 D2 D3 D7 ± 1d D14 ± 1d D21 ± 1d D28 ± 1d
History X
Age/Weight/Height/sex X
P h y s i c a l  e x a m i n a t i o n / V i t a l  s i g n s XXXX X X X X X
Clinical safety XXXX X X X X X
P a r a s i t o l o g i c a l  e x a m i n a t i o n XXXX X X X X X
Haemoglobina XX X b X( X )
Platelets + leukocytes X X Xb X( X )
Blood glucosea X( X )
Blood creatinine X X Xb X( X )
AST/ALT X X Xb X( X )
Preparation of filter paper blood spot samples for PCR X X X X X (X)
Study treatment X X X
C o n c o m i t a n t  m e d i c a t i o n XXXX X X X X ( X )
a in the event of onset of severe indicators; b in the event of an abnormal value on D7; (x) if necessary.Malaria Journal 2009, 8:125 http://www.malariajournal.com/content/8/1/125
Page 4 of 12
(page number not for citation purposes)
consisted of a physical examination combining evalua-
tion of clinical safety and measurement of vital signs. Axil-
lary temperature was measured using an electronic
thermometer. Blood pressure and pulse were measured
after a 10-minutes rest in sitting position. Blood samples
were collected on Days 0, 7 and 28 for parasitology (par-
asites count), haematology (leucocytes and platelets
count; haemoglobin level) and biochemistry (blood glu-
cose, creatinine, alanine aminotransferase ALT, aspartate
aminotransferase AST). Blood samples were exceptionally
collected once more on Day 14 if abnormal results were
observed on Day 7.
Clinical efficacy was assessed by grading the pre-existing
clinical signs and combining them with the temperature
values. Parasitological efficacy was based on asexual para-
sitaemia, although a gametocyte count was also systemat-
ically performed. The following clinical symptoms were
assessed systematically at each visit and graded as absent,
mild, moderate, severe or very severe: perspiration, head-
ache, chills, pain (specifying topography), jaundice,
asthenia, dizziness, anorexia, skin fold, skin rash,
hepatomegaly, pruritus. Splenomegaly was estimated
according to the Hackett scale [15]. Vomiting and stools
were quantified and the presence of diarrhea investigated.
The primary endpoint was the rate of adequate parasito-
logical and clinical response after PCR correction on Day
28, following the 2003 in vivo WHO protocol. Clinical
safety was monitored through regular patient interviews
with regards to the occurrence of adverse events following
the previous visit.
Laboratory analyses
Fingerpick blood samples were collected for parasitologi-
cal checking at enrolment and at successive follow-up vis-
its. Thin and thick smears were obtained and stained with
May Grünwald-Giemsa. Filter paper dried blood spot
samples were retained on filter paper for later PCR analy-
sis in case of recurrent parasitaemia. Blood samples for
parasitological count were analyzed at local centers under
their own procedures. Giemsa-stained thick blood smears
were read by experienced microscopy practitioners who
were blinded to treatment allocation. Parasite densities
were calculated by counting the number of asexual and
sexual P. falciparum parasites until 300 leukocytes were
observed and then converting this figure into parasites
(trophozoits and/or gametocytes) per microliter of blood,
assuming an average leukocyte count of 7,500/μL. For
quality control purposes, a random sample of at least 10%
of all slides analyzed at each site, as well as all slides
detected as positive, were re-evaluated using a blinded
procedure with respect to the original result and to the
source study center at the Malaria Research and Training
Center (MRTC), Bamako, Mali.
PCR analysis
For participants with recurrent parasitemia after day 7,
paired polymerase chain reaction (PCR) blots (from day 0
and the day of parasitemia recurrence) were analyzed for
parasite merozoite surface proteins (MSP-1 and MSP-2)
and microsatellite CA1 to distinguish between reinfection
and recrudescence [16]. DNA was obtained from Day 0
and failure day samples. Initial DNA was extracted using
the methanol method. Samples that failed to yield inter-
pretable results were re-extracted using a Qiagen Kit (Qia-
gen, Valencia, CA) according to the manufacturer's
instructions. Day 0 and failure day alleles of msp-1, msp-2,
and microsatellite Ca1 gene loci were compared. The PCR
was performed using the following primers pairs MSP1:
O1 = 5'-CACATGAAAGTTATCAAGAACTTGTC-3' and O2
= 5'-GTACGTCTAATTCATTTGCACG-3' for PCR1, N1 = 5'-
GCAGTATTGACAGGTTATGG-3' and N2 = 5'-GATT-
GAAAGGTATTTGAC-3' for PCR2; MSP2: S3 = 5'-GAAGG-
TAATTAAAACATTGTC-3' and S2 = 5'-
GAGGGATGTTGCTGCTCCACAG-3' for PCR1, S1 = 5'-
GAGTATAAGGAGAAGTATG-3' and S4 = 5'-CTAGAAC-
CATGCATATGTCC-3' for PCR2; and MICROSATELLITE
Ca1: Ca1-1L = 5'-GCTGTAAAACGTGAACAAAAA-3 and
Ca1-1R = 5'-CAATTCTGCTTCAGTTGGATT-3' for PCR1
and Ca1-L = 5'-ATTATGAACAATTCAGAC-3' and Ca1-R =
5'-GTTGTTATAGCTAATGAG-3' for PCR2. One to five
microliters of DNA was amplified for 30 cycles during the
primary PCR.
One to two microliters of the product of that amplifica-
tion was used for another 30 cycles of PCR. Each PCR was
performed with 1 μM of each primer, 200 μM of each
dNTP, and 1.5–3 mM MgCl2.
Possible outcomes were i) recrudescence, if the alleles of
the pre-treatment and post-treatment samples were the
same for msp-1, msp-2, and Ca1; ii) reinfection, if the alle-
les of the pre-treatment and post-treatment samples were
distinct for any of these three loci; iii) mixed recrudes-
cence and reinfection, if similar alleles were found in the
pre-treatment and posttreatment samples for all the mark-
ers as mentioned above, but with additional distinct alle-
les identified; and iv) indeterminate, if either or both the
pre-treatment and post-treatment samples could not be
amplified. Mixed recrudescent and re-infection cases were
computed as recrudescent.
Sample size calculation
A priori power calculations were used to determine the
sample size required to demonstrate non-inferiority
between the ASAQ group and the AL group (inter-group
difference <5%) in both the overall population and in a
target subpopulation of children under five years of age
with a type I error of 5% and a power of 80% to be able to
detect such a difference. On the basis of previous studiesMalaria Journal 2009, 8:125 http://www.malariajournal.com/content/8/1/125
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with AL [17,18], a response rate of 97% for children under
five years of age and 98% for older patients was antici-
pated. The sample size calculation estimate led to the
assumption that 174 children under five and 138 older
patients in each treatment arm would be required, making
a total target sample size of 936. Three patient popula-
tions were evaluated. The safety population comprised all
patients who received at least one dose of treatment. The
intent to treat (ITT) population comprised all patients in
the safety population, with the exception of those who
had rejected the treatment twice by vomiting following
the first administration. The per-protocol (PP) population
comprised all patients of the ITT population with the
exception of those presenting a major protocol deviation.
Statistical analysis
The primary efficacy endpoint corresponded to parasito-
logical and clinical cure on Day 28 determined in the ITT
population. The difference in the proportions of respond-
ers between the ASAQ group and AL group was estimated
using a non-inferiority analysis with respect to a 5% sig-
nificance level, according to the Binomial distribution,
using the STATXACT software program with the "noninf"
option (non-inferiority delta of 5%). Categorical variables
were compared with the χ2 test or Fisher's exact test, nor-
mally distributed quantitative variables with Student's t-
test and other quantitative variables with the Wilcoxon
test. Missing data were not replaced. All statistical analyses
were performed centrally using SAS version 8.2 software
(SAS Institute, Cary, North Carolina, USA).
Ethical issues
This study was conducted according to the Declaration of
Helsinki and existing national legal and regulatory
requirements. The protocol was submitted and approved
by the appropriate ethics committees and institutional
review boards in each participating country. Written
informed consent was obtained from each participant or
their parent or guardian in case of minors. If patients were
unable to sign, a fingerprint was applied on the consent
form. In case of patients unable to read, the information
was read and explained to them in the appropriate lan-
guage. In such cases, the presence of a witness who also
signed the consent form to confirm that the patient had
freely given consent was required.
Results
Overall, 941 patients were randomized to be included in
one of the three therapeutic arms. Since one patient
(0.1%) did not receive any study medication, the safety
population consisted of 940 patients. Table 2 displays
patient features at enrolment time. Four patients (0.4%)
were excluded on Day 0 after repeated rejection of their
first drug intake. The flow of patients through the study is
displayed in Figure 1. No significant differences in the fre-
quency or nature of premature study discontinuations
were observed between treatment groups, or in the fre-
quency or the nature of major protocol deviations. On
Day 28, the per-protocol population consisted of 857
patients. Globally, frequency and severity of signs and
symptoms of malaria were equivalent between the three
treatment groups and between the two age-group strata
(Table 3).
Clinical and parasitological responses to treatments
PCR-corrected clinical and parasitological cure rates on
Day 28 in the ITT population are shown in Table 4. The
two-sided 90% confidence interval of the difference
between the ASAQ1 group and the AL group in the pro-
portion of patients with adequate clinical and parasitolog-
ical response (ACPR) ranged from -0.03 to 0.03. The
upper limit of the confidence interval (0.03) was inferior
to the pre-specified non-inferiority boundary of 0.05. This
indicates that ASAQ1 is not inferior to AL. Similar find-
ings were obtained in the PP population with ACPR for
280 (98.9%) patients in the ASAQ1 group, 285 (100.0%)
in the ASAQ2 group and 285 (98.6%) in the AL group.
Subgroup analyses were performed to assess treatment
efficacy in three different age groups (Table 5). The PP
analysis confirmed the non-inferiority of the ASAQ1 ver-
sus AL treatment group in the <5 year subgroup. The two-
sided 90% confidence interval of the difference in
response rates between the two treatment groups ranged
from -0.0526 to 0.0181. Comparison between the parasi-
tological and clinical cure rate observed in the ASAQ2
group and that of the two other groups demonstrated
non-inferiority in the twice daily group. In the ITT popu-
lation, the two-sided 90% confidence intervals were -0.03
to 0.03 for the difference in therapeutic response rate
between ASAQ2 and ASAQ1 and -0.02 to 0.04 for the dif-
ference between ASAQ2 and AL.
For all five sites (Table 6), more than 90% of patients
showed a PCR-uncorrected ACPR. A number of cases of
re-infection were reported, namely one in Cameroon, five
in Madagascar, 59 in Mali, and 21 in Senegal (21 in Keur-
Socé and none in Mlomp). Regarding the primary end-
point, no centre-related effect was observed.
Parasitic clearance and resolution of clinical symptoms
At enrolment, patients in the three treatment groups had
similar mean parasite densities. Parasitic clearance rates
were at similar levels at any time and independently of the
treatment groups considered: 1.74 ± 0.60; 1.69 ± 0.60 and
1.73 ± 0.59 days in the ASAQ1, ASAQ2 and AL groups
respectively (Table 7). The number of gametocyte carriers
first increased on Day 1 but dropped from Day 2 in all
treatment groups to reach zero on Day 21 in the ASAQ1
group and on Day 14 in the AL group (Figure 2).Malaria Journal 2009, 8:125 http://www.malariajournal.com/content/8/1/125
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Rapid clinical improvement was recorded within the three
treatment groups. More than 90% of patients had no fever
within 24 hours after drug administration. A similar
reduction in the prevalence of other symptoms was gener-
ally observed as well. Nevertheless, differences between
treatment groups for three symptoms were observed only
at certain times; vomiting on Day 1 (higher in the ASAQ1
group), asthenia on Day 2 (higher in ASAQ2 group) and
headache on Day 3 (higher in the ASAQ1 group).
Drug safety
Overall, 275 patients (29.3%) in the safety population
presented at least one emergent adverse event, of which
nature, incidence and intensity were similar between the
three treatment groups. Among them, the most frequently
reported ones included intestinal parasitic infections
(5.4% of all patients; all cases were recorded in Keur-Socé,
diagnosed with abdominal symptoms consistent with
previous epidemiological studies, but without parasito-
logical confirmation), bronchitis (4.7%) and diarrhoea
(3.0%). Investigators considered 20.4% of the emergent
adverse events as treatment-related (26.9% in the ASAQ1
group, 20.7% in the ASAQ2 group and 12.3% in the AL
group). A significant difference between treatment groups
(χ2 test, p = 0.01) was observed in case of mild to moder-
ate somnolence although this was reported only in ASAQ
groups in Madagascar (15 children under 14 years of age
and two adult patients). Treatment-related adverse events
(88.5%) – mainly of mild or moderate intensity – essen-
tially concerned the nervous (24.4%; mostly insomnia
and somnolence) and gastrointestinal systems (16.7%).
Overall, 122 (13.0%) treated patients experienced vomit-
ing or rejection episodes in the first half-hour after treat-
ment administration from Day 0 to Day 2. No significant
Patient flow through the study Figure 1
Patient flow through the study. AS: artesunate; AQ: amodiaquine; A: artemether; L: lumefantrine; ITT: intent to treat; PP: 
per protocol; MPV: major protocol violation; PSD: premature study discontinuation.
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difference was recorded between the treatment groups (p
= 0.26) although the subgroup including patients under
five years of age was significantly more affected by vomit-
ing and rejection. Two cases of rashes reported by investi-
gators as treatment-related were submitted to
dermatologists for expertise, with no clear diagnosis
established. With respect to clinical symptoms occurring
under treatment, a few cases of vomiting were reported in
7.4% of patients, pain in 2.5%, anorexia in 1.8%, pruritus
in 1.7%, diarrhoea in 1.3%, asthenia in 0.9%, headache in
0.6% and chills in 0.4%.
No statistical difference was observed between treatment
groups in the population presenting abnormal values for
haemoglobin, neutrophils, ALT or creatinine. The number
of patients with abnormal values for haemoglobin
dropped from 50.3% to 32.4% between Day 0 and Day
28. It is worth mentioning that, for all patients whose hae-
moglobin values were abnormal on Day 28, these values
were already abnormal prior to treatment start. The pro-
portion of patients presenting abnormal platelet counts
also decreased during the study from 17.7% to 1.1% dur-
ing the same time lapse. Conversely the percentage of
patients with abnormal neutrophil values increased from
1.8% to 8.4%. No statistical difference was observed
between treatment groups. Six patients out of seven with
severe neutropenia on day 28 kept being monitored after
the study completion. In less than four weeks, white
blood cell count normalized in all patients. Even though
the seventh patient could not be tracked any further due
Table 2: Characteristics of patients in the safety population at inclusion.
ASAQ1 group
(N = 313)
ASAQ2 group
(N = 315)
AL group
(N = 312)
Age (years)
Mean ± SD 9.5 ± 10.8 9.1 ± 9.8 9.4 ± 10.7
< 5 years 146 (46.6) 148 (47.0) 142 (45.5)
≥ 5 years 167 (53.4) 167 (53.0) 170 (54.5)
Gender
Male 176 (56.2) 170 (54.0) 167 (53.5)
Female 137 (43.8) 145 (46.0) 145 (46.5)
Weight (kg) 24.8 ± 18.8 24.6 ± 17.7 24.6 ± 17.4
Parasite density (/μL) 37780.9 ± 45651.6 41863.0 ± 49049.1 33958.3 ± 41473.5
Gametocyte density (/μL)* 173.1 ± 296.5
(n = 14)
256.0 ± 317.3
(n = 14)
376.0 ± 1037.2
(n = 15)
ASAQ1: ASAQ 1 daily intake; ASAQ2: ASAQ 2 daily intakes; AL: AL 2 daily intakes
Data are presented as mean ± SD for quantitative variables and as patient numbers (%) for categorical variables. *Information on gametocyte 
density is only provided for the small number of subjects (N = 43 overall) with gametocytaemia at inclusion.
Table 3: Clinical characteristics at inclusion in the safety population.
ASAQ1 group
(N = 313)
ASAQ2 group
(N = 315)
AL group
(N = 312)
Axillary temperature (°C) 37.94 ± 1.09 38.04 ± 1.04 37.92 ± 1.07
Asthenia 272 (86.9%) 277 (87.9%) 270 (86.5%)
Anorexia 260 (83.1%) 253 (80.3%) 250 (80.1%)
Headache* 172/212 (81.1%) 191/231 82.7%) 181/219 (82.6%)
Chills 150 (47.9%) 156 (49.5%) 147 (47.1%)
Perspiration 146 (46.6%) 153 180 (57.1%) 147 183 (58.7%)
Dizziness* 53/165 (32.1%) 50/185 (27.0%) 48/165 (28.9%)
Pain* 96/313 (31.2%) 89/314 (28.3%) 87/312 (28.3%)
Jaundice 10 (3.2%) 2 (0.6%) 2 (0.6%)
Pruritus 1 (0.3%) 3 (1.0%) 3 (0.9%)
Skinfold None 3 (0.9%) 1 (0.3%)
Skin rash None 1 (0.3%) None
Vomiting 143 (45.8%) 153 (48.6%) 164 (52.7%)
Diarrhoea 9 (2.9%) 3 (1.0%) 8 (2.6%
Hepatomegaly 3 (0.9%) 5 (1.6%) 1 (0.3%)
Splenomegaly 31 (9.9%) 34 (10.8%) 32 (10.3%)
Data are presented as mean ± SD for quantitative variables and as patient numbers (%) for categorical variables.
*Information on these self-reported symptoms was not available for young children; the number of patients for whom data was available is thus 
indicated and used to calculate percentage values.Malaria Journal 2009, 8:125 http://www.malariajournal.com/content/8/1/125
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to relocation abroad, signs of well-being could be con-
firmed through interviews of his relatives still residing on
the study site.
The proportion of patients presenting abnormal creati-
nine values remained stable during the study (20.2% at
baseline and 20.4% at D28). For AST and ALT, the propor-
tion of patients with abnormal values decreased during
the study from 31.5% on Day 0 to 20.9% on Day 28 for
AST, and from 9.2% to 6.0% for ALT. Abnormal values
reported for these enzymes were of mild intensity. Except
for anemia recorded as an adverse event in seven patients,
no abnormal laboratory values were reported as adverse
events by the investigators.
Two patients died during the study: one patient in the
ASAQ1 group passed away after a lung infection and ane-
mia on Day 3 while one patient in the AL group fell into
a fatal coma of unknown cause on Day 1. Investigators did
not attribute those deaths to study treatment. One other
serious adverse event was reported in the ASAQ1 group,
corresponding to a case of severe anemia requiring hospi-
talization (related to treatment according to the investiga-
tor). This event occurred on the fifth day after the last
intake of treatment and the patient recovered after hospi-
talization.
Three patients in the ASAQ1 group discontinued the study
due to adverse events (persistence of severe vomiting,
fatigue, vertigo and asthenia). These events were consid-
ered by the investigator to be severe and probably related
to treatment. All patients recovered though.
Discussion
By demonstrating the non-inferiority of the therapeutic
efficacy of ASAQ with respect to AL, this study shows that
remarkably accurate clinical and parasitological response
can be obtained in patients suffering from uncomplicated
P. falciparum malaria after treatment with this new formu-
lation. These results are consistent with those from a pre-
vious study where AS+AQ were routinely used as multiple
tablets (loose combination) in Mali [6], Senegal [19] and
in Madagascar [20]. In the per-protocol population the
cure rate was >98% in all treatment groups. There was no
evidence of clustering of treatment failure in any geo-
graphical area and response rates were equivalent in chil-
dren under five and in older children or adults. Despite of
the unavoidable epidemiological versatility related to
study sites, such homogenous observations reinforce the
confidence in the results depicted in this work.
The two ASAQ1 and ASAQ2 regimens showed similar effi-
cacy and tolerability. This indicates that both regimens are
suitable from a clinical point of view, even though ASAQ1
dosing can be expected to improve general compliance
thanks to an easier dosage compared to ASAQ2. Consid-
ering the present ASAQ packaging, an appropriate dosing
may rely on the intake of one tablet per day for children
and teenagers, and two tablets once a day for adults. Such
a simple administration should help the communities
better understand and comply with the treatment.
In agreement with previous studies on AS + AQ men-
tioned above, all three ACT regimens tested in this work
induced a rapid parasitic clearance within three days and
a 50% decrease of gametocytaemia in two weeks to reach
the complete gametocytes elimination in most of the
patients at the end of the study (Day 28). These results
confirm those from Sowunmi et al, [21] (study on chil-
dren in Nigeria) that patients treated with AS or AS + AQ
had significantly shorter parasite clearance times and
lower gametocyte carriage rates than those treated with
Table 4: PCR-corrected treatment responses in the ITT population on D28.
Outcome ASAQ1
(N = 310)
ASAQ2
(N = 315)
AL
(N = 311)
Total
5
Possible failure (information unavailable) 12
(3.9%)
16
(5.1%)
9
(2.9%)
37
(4.0%)
Late clinical failure None None 2
(0.6%)
2
(0.2%)
Late parasitological failure 3
(1.0%)
None 3
(1.0%)
6
(0.6%)
Adequate clinical and parasitological response 295
(95.2%)
299
(94.9%)
297
(95.5%)
891
(95.2%)
Table 5: PCR-corrected treatment responses in the PP 
population according to age.
Age group ASAQ1
(N = 283)
ASAQ2
(N = 285)
AL
(N = 289)
Total
(N = 857)
< 5 years 132/134
(98.5%)
137/137
(100%)
129/133
(97.0%)
398/404
(98.5%)
5 – 14 years 97/98
(99.0%)
106/106
(100%)
106/106
(100%)
309/310
(99.7%)
≥ 14 years 51/51
(100%)
42/42
(100%)
50/50
(100%)
143/143
(100%)Malaria Journal 2009, 8:125 http://www.malariajournal.com/content/8/1/125
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AQ alone. Those observations as well strongly support
that ASAQ can bring the gametocyte carriage rates to a
very low level hence contribute to reduce transmission
rates of Plasmodium sp.
Since fever abated within three days in all but three
patients and other malaria symptoms also resolved rap-
idly in every group, all treatments could be considered
well tolerated in terms of safety. They all present a similar
clinical and biological safety profile and no unexpected
safety issues emerged during the course of the study. Cases
of somnolence following ASAQ were reported only in a
few children from Madagascar, essentially on Day 0, but
this diagnosis relied on (anxious) mother or caretakers
facing a "sleepy" episode. Seven cases of severe transient
and asymptomatic neutropenia occurred during this study
independently of the treatment group. In a cohort of 382
Ugandan patients treated with AS + AQ, AQ + SP or AL,
Maiteki-Sebuguzi et al [22] reported a patient presenting
repeated multiple transient neutropenic episodes, includ-
ing a severe one after treatment with AS + AQ. In this con-
text, it could be interesting to perform in-depth
longitudinal safety monitoring of ASAQ as well as other
ACTs with respect to neutropenia evolution throughout
treatment courses.
In Africa, the current national policy approach for malaria
control is to strengthen the fight through a global plan of
elimination, involving reduction of malaria incidence to a
very low predetermined level [23]. Besides vector control
by using insecticide-treated bed nets and indoor spraying
of insecticides, the use of anti-malarial drugs for cure and
prevention purposes plays a pivotal role in the fulfillment
of this objective. The challenge still relies on the introduc-
tion of anti-malarial drugs at the community level outside
healthcare facilities since this strategy offers a range of
advantages. Firstly, many countries have adopted commu-
nity case management as a national strategy for malaria
Table 6: Efficacy evaluation on D28 after PCR correction by center (ITT population)
Clinical evaluation ASAQ1
(N = 310)
ASAQ2
(N = 315)
AL
(N = 311)
Total
(N = 936)
Cameroon
Possible failure (information unavailable) 3 (5.6%) 8 (14.5%) 4 (7.1%) 15 (9.1%)
Early treatment failure 0 0 0 0
Late clinical failure 0 0 0 0
Late parasitological failure 0 0 0 0
Adequate clinical and parasitological response 51 (94.4%) 47 (85.5%) 52 (92.9%) 150 (90.9%)
Madagascar
Possible failure (information unavailable) 0 2 (3.3%) 0 2 (1.1%)
Early treatment failure 0 0 0 0
Late clinical failure 0 0 1 (1.7%) 1 (0.6%)
Late parasitological failure 1 (1.7%) 0 0 1 (0.6%)
Adequate clinical and parasitological response 58 (98.3%) 58 (96.7%) 59 (98.3%) 175 (97.8%)
Mali
Possible failure (information unavailable) 2 (3.0%) 3 (4.4%) 2 (3.0%) 7 (3.5%)
Early treatment failure 0 0 0 0
Late clinical failure 0 0 0 0
Late parasitological failure 2 (3.0%) 0 2 (3.0%) 4 (2.0%)
Adequate clinical and parasitological response 62 (93.9%) 65 (95.6%) 63 (94.0%) 190 (94.5%)
Senegal – Keur Soce
Possible failure (information unavailable) 2 (2.1%) 1 (1.1%) 2 (2.2%) 5 (1.8%)
Early treatment failure 0 0 0 0
Late clinical failure 0 0 0 0
Late parasitological failure 0 0 1 (1.1%) 1 (0.4%)
Adequate clinical and parasitological response 93 (97.9%) 91 (98.9%) 86 (96.6%) 270 (97.8%)
Senegal – Mlomp
Possible failure (information unavailable) 5 (13.9%) 2 (5.0%) 1 (2.6%) 8 (7.0%)
Early treatment failure 0 0 0 0
Late clinical failure 0 0 1 (2.6%) 1 (0.9%)
Late parasitological failure 0 0 0 0
Adequate clinical and parasitological response 31 (86.1%) 38 (95.0%) 37 (94.9%) 106 (92.2%)Malaria Journal 2009, 8:125 http://www.malariajournal.com/content/8/1/125
Page 10 of 12
(page number not for citation purposes)
control. Secondly, incorporating ACT into community
case management has been evaluated in Ghana, Nigeria
and Uganda and found to be both feasible and acceptable
[24]. It was shown that the success of these programs
mainly depends on the presence of well-trained and well-
supervised Community Medicine Distributors who will
be best suited to manage patients' treatment in villages
and provide good therapeutic coverage in an acceptable
and proactive way. Finally, in some areas exposed to an
epidemic risk of malaria, such as the Highlands of Mada-
gascar [25,26], mass drug administration has been inte-
grated into the campaign to combat malaria epidemics
[27]. In these situations, the ASAQ fixed-dose tablets
could be a key element in community deployment of
ACT. Drug efficacy is a necessary but insufficient require-
ment to reach these goals. Indeed efforts must be made to
make ASAQ affordable and accessible to a wider range of
national malaria programs and communities.
Conclusion
The ASAQ fixed-dose combination administered once
daily provided clinical and parasitological efficacy compa-
rable to AL. Non-inferiority of ASAQ with respect to AL
was also demonstrated in children under five years of age.
Dividing the ASAQ intake into two daily doses does not
confer any advantage in terms of efficacy or safety. The
ASAQ fixed-dose combination thus offers an effective and
safe option to treat uncomplicated P. falciparum malaria in
Gametocyte clearance Figure 2
Gametocyte clearance. Data are presented as the number of patients with gametocytes.
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Treatment duration (days)
| artesunate-amodiaquine once daily
z artesunate-amodiaquine twice daily
 artemether-lumefantrine twice daily
Table 7: Parasitic clearance
Treatment duration ASAQ1
(N = 310)
ASAQ2
(N = 315)
AL
(N = 311)
Total
(N = 936)
Day 0
N 310 (100%) 315 (100%) 311 (100%) 936 (100%)
Density 37781 ± 45652 41863 ± 49049 33958 ± 41474 37880 ± 45575
Day 1
N 198 (64.7%) 194 (61.8%) 206 (66.5%) 598 (64.3%)
Density 3297 ± 8403 3137 ± 14753 3764 ± 14809 3406 ± 13002
Day 2
N 26 (8.6%) 24 (7.7%) 25 (8.1%) 75 (8.1%)
Density 503 ± 787 914 ± 3230 1098 ± 2585 833 ± 2383
Day 3
N None 2 (0.6%) 4 (1.3%) 6 (0.7%)
Density - 154 ± 76 464 ± 296 361 ± 282
Data are presented as the number of patients with parasites (N) and as the mean parasite density ± SD for the patients with parasitaemia.Malaria Journal 2009, 8:125 http://www.malariajournal.com/content/8/1/125
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adults and children. Effectiveness studies are required
now to estimate whether combining a limited number of
tablets with a single daily dosage will have a real positive
impact on patient compliance. The successful deployment
of ASAQ fixed-dose requires operational pharmacovigi-
lance programs which should be conducted to assess its
long-term safety profile.
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